Cyclooxygenases-2 (COX-2) and Prostaglandin E2 (PGE2), which are important in chronic
inflammatory diseases, can increase tumor incidence and promote tumor growth and …

The regulatory approval of ipilimumab (Yervoy) in 2011 ushered in a new era of cancer
immunotherapies with durable clinical effects. Most of these breakthrough medicines are …

The initiation of an intestinal tumour is a probabilistic process that depends on the
competition between mutant and normal epithelial stem cells in crypts. Intestinal stem cells …

There is a clinical need for new, more effective treatments for chronic and debilitating
inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis. In this …

Cyclooxygenase-2 isozyme is a promising anti-inflammatory drug target, and
overexpression of this enzyme is also associated with several cancers and …

Chronic inflammation is a known risk factor for gastrointestinal cancer. The evidence that
nonsteroidal anti-inflammatory drugs suppress the incidence, growth, and metastasis of …

The group IV phospholipase A 2 (PLA 2) family is comprised of six intracellular enzymes
(GIVA,-B,-C,-D,-E, and-F) commonly referred to as cytosolic PLA 2 (cPLA 2) α,-β,-γ,-δ,-ε, and …

Previously, a synbiotic combination of probiotic Lactobacillus gasseri 505 (LG) and a new
prebiotic, Cudrania tricuspidata leaf extract (CT) in fermented milk, designated FCT, showed …

According to numerous animal studies, adverse environmental stimuli, including physical,
chemical, and biological factors, can cause low‐grade chronic inflammation and subsequent …

Secreted proteins are one of the direct molecular mechanisms by which microbiota influence
the host, thus constituting a promising field for drug discovery. Here, through bioinformatics …